vimarsana.com

Latest Breaking News On - Frank kochinke - Page 1 : vimarsana.com

Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery Technologies

San Diego, California (Newsfile Corp. - May 10, 2022) - Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery

United statesSan diegoKostenloser wertpapierhandelPatrick eckstromFrank kochinkeBryan arrayalesMycrodose therapeutics incCalifornia newsfile corpMicrodosing technologyChief science officerMycrodose therapeuticsProtected sustained microdosing technology

Mycrodose Therapeutics Announces First Clinical Candidate for Ketamine-Based Drug Delivery Device for Oral Mucositis

San Diego, California (Newsfile Corp. - March 31, 2022) - Mycrodose Therapeutics ("Mycrodose"), a leading US pharmaceutical company specializing in the development of advanced drug delivery technologies

United statesSan diegoKostenloser wertpapierhandelPatrick eckstromChristian yavorskyFrank kochinkeMycrodose therapeutics incCalifornia newsfile corpWorld health organizationMicrodosing technologyChief research officerChief science officerChad connerChief executive officerProtected sustained microdosing technologyMycrodose therapeutics

Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States

Press release content from KISSPR. The AP news staff was not involved in its creation.

United statesSan diegoPatrick eckstromPsilocybe cubensisFrank kochinkeDrug administrationMicrodosing technologyUs drug enforcement agencyNewsfile corpMycrodose therapeutics incMycrodose scientific teamSchedulei researchVancouver canadaStory presswireMycrodose therapeuticsIntellectual property

Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States

DEA approval allows Mycrodose Therapeutics to become the first vertically integrated US Pharmaceutical company utilizing psilocybin-based psychedelic medicine. Approval also allows Mycrodose the ability

United statesSan diegoKostenloser wertpapierhandelPatrick eckstromPsilocybe cubensisFrank kochinkeDrug administrationMicrodosing technologyUs drug enforcement agencyMycrodose therapeutics incCalifornia newsfile corpMycrodose scientific teamSchedulei researchMycrodose therapeuticsIntellectual propertyEnforcement agency

Mycrodose Therapeutics Receives US DEA Schedule I License to Research Four (4) Psychedelic Compounds

San Diego, California (PRWEB) August 20, 2021 Mycrodose Therapeutics is pleased to announce that the company has been approved by the United States Drug

State of californiaUnited statesSan diegoPatrick eckstromFrank kochinkeResearch advisory boardUs food drug administrationUnited states drug enforcement agencyMycrodose therapeutics an advanced drug delivery companyMycrodose therapeuticsAdvanced drug deliveryChief scienceCalifornia attorney generalDrug administrationMycrodose therapeuticSchedulei license

vimarsana © 2020. All Rights Reserved.